2024
The cascade of care for commercially-insured persons with opioid use disorder and comorbid HIV and HCV infections
Ivasiy R, Madden L, DiDomizio E, Johnson K, Machavariani E, Ahmad B, Oliveros D, Ram A, Kil N, Altice F. The cascade of care for commercially-insured persons with opioid use disorder and comorbid HIV and HCV infections. Drug And Alcohol Dependence 2024, 263: 112410. PMID: 39159600, DOI: 10.1016/j.drugalcdep.2024.112410.Peer-Reviewed Original ResearchOpioid use disorderXR-NTXUse disorderHCV infectionPrescribed MOUDOpioid use disorder cascadePrevalence of opioid use disorderRetrospective cohort studyHigher treatment retentionCascade of careConcurrent infectious diseasesSix-month retentionHCV/HIV coinfectionComorbid HIVCohort studyHospital-based settingPrescribed methadoneHCVMOUD initiationHIVHCV epidemicOpioidMethadoneMOUD prescriptionsTreatment retentionT107 Perceived Importance of Counseling Among Patients Receiving Methadone Treatment
Beitel M, Saeed G, Gazzola M, Eggert K, Roehrich T, Madden L, Barry D. T107 Perceived Importance of Counseling Among Patients Receiving Methadone Treatment. Drug And Alcohol Dependence 2024, 260: 110556. DOI: 10.1016/j.drugalcdep.2023.110556.Peer-Reviewed Original ResearchM135 Counselor Terminological Preferences for "Craving,” “Euphoria,” and “Withdrawal” Among Patients Receiving Methadone Treatment
Gazzola M, Beitel M, Buck K, Cammack K, Saeed G, Eggert K, Roehrich T, Madden L, Barry D. M135 Counselor Terminological Preferences for "Craving,” “Euphoria,” and “Withdrawal” Among Patients Receiving Methadone Treatment. Drug And Alcohol Dependence 2024, 260: 110415. DOI: 10.1016/j.drugalcdep.2023.110415.Peer-Reviewed Original ResearchS94 Patient Perspectives on an Open Access Model for Methadone Treatment: A Research and Process Improvement Protocol
Madden L, Farnum S, Eggert K, Cannata E, Hermes G, DiMeola K, Hoffman K, Barry D. S94 Patient Perspectives on an Open Access Model for Methadone Treatment: A Research and Process Improvement Protocol. Drug And Alcohol Dependence 2024, 260: 110205. DOI: 10.1016/j.drugalcdep.2023.110205.Peer-Reviewed Original ResearchS84 Lived Experiences of Addiction Counselors: A Protocol Exploring Stigma in a Time of Regulatory Change Within Opioid Treatment Programs
Eggert K, Madden L, Mabry B, Gjoni-Markaj E, Hoffman K, DiMeola K, Cannata E, Farnum S, Hermes G, Barry D. S84 Lived Experiences of Addiction Counselors: A Protocol Exploring Stigma in a Time of Regulatory Change Within Opioid Treatment Programs. Drug And Alcohol Dependence 2024, 260: 110195. DOI: 10.1016/j.drugalcdep.2023.110195.Peer-Reviewed Original ResearchW96 Scaling up Opioid Agonist Therapies in Ukraine Before the War: Implementation Factors Related to Disruptions From Legislative Reform and COVID-19
Madden L, Ivasiy R, Polonsky M, Farnum S, Galvez S, Meteliuk A, Bromberg D, Altice F. W96 Scaling up Opioid Agonist Therapies in Ukraine Before the War: Implementation Factors Related to Disruptions From Legislative Reform and COVID-19. Drug And Alcohol Dependence 2024, 260: 110714. DOI: 10.1016/j.drugalcdep.2023.110714.Peer-Reviewed Original ResearchThe impact of emergency guidance to the COVID‐19 pandemic on treatment entry, retention and mortality among patients on methadone in Ukraine
Ivasiy R, Madden L, Meteliuk A, Machavariani E, Ahmad B, Zelenev A, Desai M, Bromberg D, Polonsky M, de Leon S, Farnum S, Islam Z, Altice F. The impact of emergency guidance to the COVID‐19 pandemic on treatment entry, retention and mortality among patients on methadone in Ukraine. Addiction 2024, 119: 1585-1596. PMID: 38807448, DOI: 10.1111/add.16565.Peer-Reviewed Original ResearchOpioid agonist therapyTake-home dosesCOVID-19 guidancePre-COVID cohortAgonist therapyOptimal doseTreatment retentionEmergency guidanceEffective HIV prevention strategiesAdult HIV prevalenceHIV prevention strategiesMinistry of HealthImprove treatment retentionMethadone dosePatient survivalTime-dependent predictorsProspective cohortHIV prevalencePredictors of treatment retentionGovernmental clinicsPrimary outcomeHazard ratioPatient enrollmentPatientsMethadone patientsPerceptions of Community Corrections and Treatment Experience: A Qualitative Study Among People With Incarceration Histories Receiving Outpatient Methadone Treatment.
Gaeta Gazzola M, Oberleitner L, Hoffman K, Eller A, Madden L, Marcus R, Oberleitner D, Beitel M, Thompson E, Zheng X, Barry D. Perceptions of Community Corrections and Treatment Experience: A Qualitative Study Among People With Incarceration Histories Receiving Outpatient Methadone Treatment. Substance Use & Addiction Journal 2024, 29767342241238837. PMID: 38551080, DOI: 10.1177/29767342241238837.Peer-Reviewed Original ResearchCommunity corrections officersCommunity corrections systemCorrection systemCommunity correctionsTreatment facilitatorsOpioid use disorderCorrective experiencesMethadone treatmentSubstance use disorder careCommunity supervisionCorrectional officersQualitative studyCoercive treatmentIncarceration historyOutpatient methadone treatmentIncarcerationDemographic surveyQualitative research teamNegative experiencesNegative perceptionsCommunitySemistructured interviewsPositive perceptionsInterviewsParoleA Quantitative Examination of Illness Models Among People With Opioid Use Disorder Receiving Methadone Treatment
Gazzola M, Carmichael I, Thompson E, Beitel M, Madden L, Saeed G, Hoffman K, Hammouri M, Hsaio C, Barry D. A Quantitative Examination of Illness Models Among People With Opioid Use Disorder Receiving Methadone Treatment. Journal Of Addiction Medicine 2024, 18: 262-268. PMID: 38446859, DOI: 10.1097/adm.0000000000001282.Peer-Reviewed Original ResearchBrain disease modelMethadone treatmentTreatment beliefsIllness modelAssociated with beliefsOpioid use disorderUse disorderOutpatient opioid treatment programAddiction modelTreatment programsOpioid treatment programsAddictionMethadoneMultivariate analysisScale agreementIllnessDisordersCounselingBrainBeliefsDisease modelsOpioidPatientsStatistical significanceMultivariate regressionIntegrating methadone into primary care settings in Ukraine: effects on provider stigma and knowledge
Bromberg D, Machavariani E, Madden L, Dumchev K, LaMonaca K, Earnshaw V, Pykalo I, Filippovych M, Haddad M, Dvoriak S, Altice F. Integrating methadone into primary care settings in Ukraine: effects on provider stigma and knowledge. Journal Of The International AIDS Society 2024, 27: e26202. PMID: 38379179, PMCID: PMC10879646, DOI: 10.1002/jia2.26202.Peer-Reviewed Original ResearchConceptsPrimary care clinicsStigma reduction interventionsOpioid agonist therapyClinicians' attitudesStigma constructsHIV preventionReduction interventionsEvidence-based HIV preventionCluster randomized controlled trialEvidence-based carePrimary care settingIntegrated care sitesDirect providersRandomized controlled trialsProvider stigmaCare clinicsCare sitesHIV careCare settingsHealth outcomesClinical staffSubstance use disordersLinear mixed-effects modelsTreatment continuumImprove attitudesPreferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey.
Bromberg D, Madden L, Fraenkel L, Muthulingam D, Rhoades D, Dvoriak S, Dumchev K, Pykalo I, Altice F. Preferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey. PLOS Global Public Health 2024, 4: e0002725. PMID: 38277422, PMCID: PMC10817130, DOI: 10.1371/journal.pgph.0002725.Peer-Reviewed Original ResearchOpioid agonist therapyWithdrawal symptomsAdverse side effectsAgonist therapySide effectsOpioid use disorderQuality-of-life improvementUse disorderCombined HIVHIV incidenceClinical decision-makingDosing frequencyRespondent-driven samplingOpioidOpioid epidemicAssess preferencesClinical concernPatient preferencesPatientsDelivery strategiesTherapyDisordersHIVPatient concernsWithdrawalCorrigendum: High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine
Galvez S, Altice F, Meteliuk A, Ivasiy R, Machavariani E, Farnum S, Fomenko T, Islam Z, Madden L. Corrigendum: High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine. Frontiers In Public Health 2024, 11: 1359708. PMID: 38274528, PMCID: PMC10809844, DOI: 10.3389/fpubh.2023.1359708.Peer-Reviewed Original ResearchStalled Scale-Up of Opioid Agonist Therapies for HIV Prevention in Kazakhstan: History, Policy, and Recommendations for Change
Liberman A, Ivasiy R, Altice F, Bromberg D, Ibragimova O, Seksenova Z, Madden L, Primbetova S, Terlikbayeva A. Stalled Scale-Up of Opioid Agonist Therapies for HIV Prevention in Kazakhstan: History, Policy, and Recommendations for Change. Journal Of Illicit Economies And Development 2024, 5: 69-77. DOI: 10.31389/jied.208.Peer-Reviewed Original Research
2023
High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine
Galvez S, Altice F, Meteliuk A, Ivasiy R, Machavariani E, Farnum S, Fomenko T, Islam Z, Madden L. High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine. Frontiers In Public Health 2023, 11: 1231581. PMID: 38098837, PMCID: PMC10720365, DOI: 10.3389/fpubh.2023.1231581.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderAgonist therapyOAT patientsCOVID-19 pandemicSubstance useTake-home dosingAdditional psychosocial supportHigher perceived stressHigh riskPerceived Stress ScalePsychiatric disordersUse disordersPatientsPatient stressPsychosocial supportCertain subgroupsSevere levelsHigh levelsHealthcare deliveryStress ScalePerceived stressTherapyExtraordinary high levelsDisordersPreferences in medications for patients seeking treatment for opioid use disorder: A conjoint analysis
Muthulingam D, Hassett T, Madden L, Bromberg D, Fraenkel L, Altice F. Preferences in medications for patients seeking treatment for opioid use disorder: A conjoint analysis. Journal Of Substance Use And Addiction Treatment 2023, 154: 209138. PMID: 37544510, DOI: 10.1016/j.josat.2023.209138.Peer-Reviewed Original ResearchConceptsOpioid use disorderRoute of administrationPatient preferencesUse disordersSymptom reliefTreatment preferencesSide effectsCross-sectional observational studyTreatment-seeking peopleChi-squared analysisOral medicationsPublic health crisisOUD treatmentTreatment uptakeWithdrawal symptomsOpioid epidemicObservational studyTreatment decisionsSTROBE checklistSustainability of treatmentPatientsMedicationsHealth professionalsUtility scoresLarger studyImproving HIV and HCV Testing in Substance Use Disorder Programs (SUDs) That Provide Medications for Opiate Use Disorder (MOUD): Role of Addressing Barriers and Implementing Universal and Site-Specific Approaches
Brooks R, Wegener M, Freeman B, Fowles C, Madden L, Tetrault J, Nichols L, Altice F, Villanueva M. Improving HIV and HCV Testing in Substance Use Disorder Programs (SUDs) That Provide Medications for Opiate Use Disorder (MOUD): Role of Addressing Barriers and Implementing Universal and Site-Specific Approaches. Health Promotion Practice 2023, 24: 1018-1028. PMID: 37439759, DOI: 10.1177/15248399231169791.Peer-Reviewed Original ResearchConceptsHIV/HCV coinfectionSubstance use disorder programsHCV testingOpiate use disorderHCV coinfectionUse disordersNominal group techniqueSubstance use disorder treatment centersCascade of careRates of HIVDisorder treatment centersQuality improvement effortsRate of testingHCV acquisitionHCV cureImproving HIVSUD clinicsHepatitis CHIV testingPrior diagnosisSubsequent referralReferral ratesHIV epidemicHIVTreatment centersLeveraging existing provider networks in Europe to eliminate barriers to accessing opioid agonist maintenance therapies for Ukrainian refugees
Nikitin B, Bromberg D, Madden L, Stöver H, Teltzrow R, Altice F. Leveraging existing provider networks in Europe to eliminate barriers to accessing opioid agonist maintenance therapies for Ukrainian refugees. PLOS Global Public Health 2023, 3: e0002168. PMID: 37440470, PMCID: PMC10343058, DOI: 10.1371/journal.pgph.0002168.Peer-Reviewed Original ResearchOpioid use disorderAgonist maintenance therapyMaintenance therapyInjection drug usePrevention of HIVGold standard treatmentRisk of HIVHigh prevalence ratesCare continuityStandard treatmentPrevalence ratesUse disordersImplementation science lensDrug useHarm reductionTreatment modelHIVPatientsClinicTherapyAddiction treatment modelsTreatmentProvidersInvasionInterview participantsCorrelates of Perceived Discrimination Related to Substance Use Disorders Among Patients in Methadone Maintenance Treatment
Nwanaji-Enwerem U, Beitel M, Oberleitner D, Gazzola M, Eggert K, Oberleitner L, Jegede O, Zheng X, Redeker N, Madden L, Barry D. Correlates of Perceived Discrimination Related to Substance Use Disorders Among Patients in Methadone Maintenance Treatment. Journal Of Psychoactive Drugs 2023, ahead-of-print: 1-11. PMID: 37399330, PMCID: PMC10761588, DOI: 10.1080/02791072.2023.2230571.Peer-Reviewed Original ResearchMethadone maintenance treatmentSubstance use disordersLogistic regression modelsUse disordersMaintenance treatmentTreatment-related characteristicsOpioid use disorderFinal logistic regression modelBSI-18 depressionAge of onsetRegression modelsMMT programDepressive symptomsMeasures of demographicsPatientsBivariate analysisSubstance abuseSignificant correlatesDisordersCorrelatesMedian splitAgeParticipantsTreatmentLikert-type scaleApplication of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study
Mistler C, Shrestha R, Gunstad J, Collins L, Madden L, Huedo-Medina T, Sibilio B, Copenhaver N, Copenhaver M. Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study. BMJ Open 2023, 13: e071688. PMID: 37399447, PMCID: PMC10314648, DOI: 10.1136/bmjopen-2023-071688.Peer-Reviewed Original ResearchConceptsOpioid use disorderMultiphase optimization strategyCognitive dysfunctionHIV preventionUse disordersPromising biomedical interventionsPre-exposure prophylaxisHIV incidence ratesHIV risk reductionHIV prevention interventionsDrug treatment settingsInstitutional review boardInformed consent formPrEP adherenceHIV prevention contentHIV infectionPrEP uptakeStudy protocolIncidence rateRisk groupsPrevention interventionsPWIDTreatment settingsReview boardEffective interventionsThe impact of body image dissatisfaction on psychological distress and health‐related quality of life among patients in methadone treatment
Carr M, Mannes Z, Oberleitner L, Oberleitner D, Beitel M, Gazzola M, Madden L, Zheng X, Barry D. The impact of body image dissatisfaction on psychological distress and health‐related quality of life among patients in methadone treatment. American Journal On Addictions 2023, 32: 460-468. PMID: 37188650, PMCID: PMC10524388, DOI: 10.1111/ajad.13432.Peer-Reviewed Original ResearchConceptsBody mass indexMethadone maintenance treatmentBody image dissatisfactionAverage body mass indexNon-Hispanic white menPsychological distressLower physical HRQoLHealth-related qualityLong-term courseLower mental HRQoLHigh psychological distressMental HRQoL.Image dissatisfactionMMT patientsObese rangePhysical HRQoLMaintenance treatmentMass indexMental HRQOLMethadone treatmentNormal weightOverweight rangeHigher body image dissatisfactionMMT outcomesPatients